Atovaquone

Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome?bc1?complex. Atovaquone is against human and ?P. falciparum?cytochrome?bc1?activity with IC₅₀ values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia^[1][2]. IC50 & Target: IC50: 460 nM (human?cytochrome?bc1); 2.0 nM (P. falciparum?cytochrome?bc1)^[1] In Vitro: Atovaquone targets to the Q_o?site of the?Plasmodium?cytochrome?bc1?complex of the mitochondrial electron transport chain^[1].
Atovaquone is against the development in the mosquito from gamete production, through fertilization, zygote formation and finally, to the development of the mature ookinete, and demonstrates an IC₅₀?of 67 nM providing further evidence of the transmission blocking potential of this molecule^[1].
In Vivo: Atovaquone (oral administration; 100 mg/kg; once daily) is against survival rates of mice, mice treated orally died within 22 days after discontinuation of sulfadiazine,while the control group died at day 14^[2].